It is important to note, however, that despite AMPK and mTOR being highly druggable master regulators of human immunity [81,82,83], the relationship between the pathogenesis of autoimmune disease and AMPK-dependent mTOR inactivation is certainly not clear cut and not many examples exist of successfully targeting human autoimmune disease through the pharmacological targeting of either AMPK or mTOR in the body of contemporary biomedical literature [84,85]. This evidence concerns the gene MTOR and autoimmune disease.